Hdac-in-4 Uses, Dosage, Side Effects and more
Hdac-in-4 is under investigation in clinical trial NCT03873025 (A Study of Hdac-in-4 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-cell Lymphoma).
| Trade Name | Hdac-in-4 |
| Generic | CXD101 |
| CXD101 Other Names | Hdac inhibitor cxd101, Hdac-in-4 |
| Type | |
| Formula | C24H29N5O |
| Weight | Average: 403.53 Monoisotopic: 403.237210574 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
